Mir v. Naz

CourtDistrict Court, E.D. New York
DecidedDecember 6, 2021
Docket1:21-cv-06340
StatusUnknown

This text of Mir v. Naz (Mir v. Naz) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mir v. Naz, (E.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -------------------------------------------------------------- MUHAMMAD T. MIR, SALMAN RIAZ, and ROCKAWAY COMMUNITY CARE CORP., d/b/a REX PHARMACY, MEMORANDUM & ORDER Plaintiffs, 21-CV-6340 (MKB)

v.

ABDUL NAZ,

Defendant. -------------------------------------------------------------- MARGO K. BRODIE, United States District Judge: On October 5, 2021, Plaintiffs Muhammad T. Mir, Salman Riaz, and Rockaway Community Care Corp, doing business as Rex Pharmacy (the “Pharmacy”), commenced a conversion, breach of contract, and breach of fiduciary duty action against Defendant Abdul Naz in New York State Supreme Court, Queens County. (State Ct. Compl., annexed to Notice of Removal, Docket Entry No. 1-2.) On November 15, 2021, Defendant filed a Notice of Removal pursuant to 28 U.S.C. §§ 1441 and 1446, seeking to remove the action to the Eastern District of New York. (Notice of Removal, Docket Entry No. 1.) Defendant alleged that the Court had original jurisdiction under 28 U.S.C. § 1331 and 18 U.S.C. § 1961, et seq. based on the federal counterclaim asserted in his answer. (Id. at ¶ 6.) On November 23, 2021, Plaintiffs filed an emergency motion to remand the action to state court. (Pls.’ Mot. to Remand to State Court (“Pls.’ Mot.”), Docket Entry No. 6.) By Order dated November 23, 2021, the Court directed Defendant to show cause why the Court should not remand the action to state court for lack of jurisdiction, (Order dated Nov. 23, 2021), and Defendant responded to the Court’s Order, (Def.’s Decl. in Opp’n to Pls.’ Mot. to Remand to State Court (“Def.’s Decl.”), Docket Entry No. 8). The Court has reviewed Defendant’s response and the Notice of Removal. As more fully explained below, the Court lacks jurisdiction and remands the action to the New York State Supreme Court, Queens County.

I. Background On October 5, 2021, Plaintiffs commenced an action against Defendant in state court, disputing Defendant’s claim of sole ownership of the Pharmacy and contesting Defendant’s decision to physically lock Plaintiffs out of the business. (State Ct. Compl. ¶¶ 30, 37, 39–43.) On November 15, 2021, Defendant filed a Notice of Removal to remove the action to the Eastern District of New York, asserting federal question jurisdiction based on his counterclaim under the Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 U.S.C. § 1961, et seq. (Notice of Removal ¶ 6.) On November 23, 2021, Plaintiffs requested leave to move to remand the case to state court, stating that Defendant was violating various restraints that the presiding state court judge

had entered by an Order to Show Cause in order to protect the viability of the Pharmacy. (Pls.’ Mot. 1.) On November 23, 2021, the Court directed Defendant to show cause why the Court should not remand the action to state court, noting that the Court did not have jurisdiction on the basis of Defendant’s RICO counterclaim. (Order dated Nov. 23, 2021.) On November 30, 2021, Defendant responded to the Court’s Order, first acknowledging that he was unaware that he could not remove the action on the basis of his counterclaim, and then arguing that the Court should nevertheless decline to remand the action to state court because the Court can exercise jurisdiction on the basis of diversity. (Def.’s Decl. ¶¶ 1–2.) Defendant contends that the Court has diversity jurisdiction because (1) Defendant is a citizen of New York, (2) Riaz is a citizen of New Jersey, (3) Mir is a citizen of New Jersey, and (4) the amount in controversy is in excess of $750,000. (Id. at ¶¶ 4,8.) As to the Pharmacy Plaintiff, Defendant contends that Plaintiffs only included the Pharmacy “[i]n an apparent attempt to

defeat diversity jurisdiction,” and further contends that the Pharmacy is “a New York corporation” that Plaintiffs “do not own.” (Id. ¶ 5.) Defendant argues that based on the response to his Freedom of Information Law request, he has learned that Plaintiffs have “affirmatively disclaimed ownership” of the Pharmacy in at least two sworn filings with the New York State Education Department, which includes the State Board of Pharmacy. (Id. ¶¶ 10,12.) Defendant notes that in these filings, Plaintiffs have attested that they have a “financial or ownership interest” in People’s Drug Rx Inc., Rex Specialty Pharmacy Corp., and Peekskill Pharmacy Inc., but not the Pharmacy. (Id. ¶¶ 13–21.) Defendant argues that because Plaintiffs have “disclaimed such ownership under oath, on at least two separate occasions,” Plaintiffs’ inclusion of the Pharmacy is “nothing more than a cynical ploy to defeat diversity jurisdiction.” (Id. ¶ 23.)

II. Discussion a. The Court lacks jurisdiction over this action Because Defendant’s Notice of Removal invokes the Court’s jurisdiction based on his RICO counterclaim and does not assert diversity jurisdiction, the Court lacks subject matter jurisdiction over this action. A notice of removal must allege a proper basis for removal under 28 U.S.C. §§ 1441 to 1445. See Agyin v. Razmzan, 986 F.3d 168, 181 (2d Cir. 2021). “[In] determining whether jurisdiction is proper, we look only to the jurisdictional facts alleged in the Notices of Removal.” Id. (quoting In re Methyl Tertiary Butyl Ether Prods. Liab. Litig., 488 F.3d 112, 124 (2d Cir. 2007)); New York v. Dickerson, No. 20-CR-208, 2020 WL 3263771, at *1 (E.D.N.Y. June 16, 2020) (“An effective petition for the removal of a state action to federal court must allege a proper basis for the removal under sections 1441 through 1445 of Title 28.” (quoting Negron v. New York, No. 02-CV-1688, 2002 WL 1268001, at *1 (E.D.N.Y. Apr. 1, 2002))). A defendant

may remove a civil action brought in state court to a federal court in “any civil action . . . of which the district courts of the United States have original jurisdiction.” 28 U.S.C. § 1441(a). A district court is required to evaluate “whether the plaintiff could have filed its operative complaint in federal court, either because it raises claims arising under federal law or because it falls within the court’s diversity jurisdiction.” Home Depot U.S.A., Inc. v. Jackson, 139 S. Ct. 1743, 1748 (2019). However, the Supreme Court has held that “[a] counterclaim . . . cannot serve as the basis for ‘arising under’ jurisdiction.” Id. (quoting Holmes Grp., Inc. v. Vornado Air Circulation Sys., Inc., 535 U.S. 826, 831 (2002)); see Sea Gate Ass’n v. Krichevsky, 18-CV-3408, 2019 WL 8587287, at *6 (E.D.N.Y. June 21, 2019) (“Notably, a defendant cannot ‘evade [the well-pleaded complaint] rule by raising a federal question in its responsive pleadings

and attempting to remove on that basis.’” (quoting Calabro v. Aniqa Halal Live Poultry Corp., 650 F.3d 163, 166 (2d Cir. 2011) (per curiam)) (alteration in original)); Sleppin v. Thinkscan.com, LLC, 55 F. Supp.

Related

Cite This Page — Counsel Stack

Bluebook (online)
Mir v. Naz, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mir-v-naz-nyed-2021.